RXEEY vs RDY
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
RXEEY · REXEL UNSP ADR EA REPR 1 ORD EUR5.00$38.39 ▲ 0.22%
RDY · Dr. Reddy's Laboratories$14.91 ▲ 2.62%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- RXEEY +16.5%
- RDY +11.1%
Head to head
| Metric | RXEEY | RDY |
|---|---|---|
| Price | $38.39 | $14.91 |
| Change today | ▲ 0.22% | ▲ 2.62% |
| Market cap | $12.42B | $12.43B |
| Return, 3 months | -10.0% | +22.7% |
| Return, year to date | +1.1% | +6.9% |
| Return, 1 year | +17.8% | +11.6% |
| P/E (TTM) | 14.5 | 42.0 |
| P/B | 1.8 | 3.0 |
| P/E percentile vs own 5y | – | 98th |
| Dividend yield | 3.65% | 0.56% |
| Revenue growth (YoY, latest qtr) | – | -1.5% |
| Net profit growth (YoY) | – | -36.0% |
| Gross margin | – | 49.5% |
| Operating margin | – | 9.5% |
| Net margin | – | 8.5% |
| Return on equity | – | 7.5% |
| Analyst target vs. price | – | -3.8% |
| Analyst buy share | – | 67% |
| RSI (14) | 46 | 78 |
| 30-day volatility | 35.4% | 26.4% |
| Max drawdown, 1 year | -20.6% | -26.0% |
| Trend read | Leaning bearish | Strong uptrend |
| Analyst consensus | – | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- RDY is the largest of the group by market value.
- RXEEY has returned the most over the past year.
- RXEEY carries the lowest trailing P/E.
- RXEEY pays the highest dividend yield.
- RDY has been the calmest stock over the last 30 days.